{"a":[{"_":"ArsenalBio sheds most of staff in pivot to in vivo CAR-T","$":{"href":"/biotech/arsenalbio-sheds-most-staff-pivot-vivo-car-t","hreflang":"en"}}]}

Summary

Arsenal Biosciences is laying off most of its staff and divesting assets as part of a strategic pivot to in vivo CAR-T therapy, following a previous workforce reduction about a year ago.